Aurora Cannabis (ACB) AI Stock Analysis

• Market Cap: $377.68M
• Dividend Yield: N/A
• Average Volume (3M): 814.59K
• Price to Earnings (P/E): 105.8
• Beta (1Y): 2.39
• Revenue Growth: 28.42%
• EPS Growth: 48.33%
• Country: CA
• Employees: 1,073
• Sector: Healthcare
• Sector Strength: 49
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.26
• Shares Outstanding: 56,453,950
• 10 Day Avg. Volume: 688,575
• 30 Day Avg. Volume: 814,591
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.73
• Enterprise Value/Revenue: 0.77
• Enterprise Value/Gross Profit: 1.96
• Enterprise Value/Ebitda: 11.17
• 1Y Price Target: $7.00
• Price Target Upside: 4.64% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 52 Neutral
• Price Target: C$7.00 ▲(4.63% Upside)

Aurora Cannabis's overall score is driven by strong earnings call results, indicating significant revenue growth and improved margins. However, financial performance challenges, particularly in profitability and cash flow, weigh down the score. Technical indicators show a positive trend, but valuation concerns due to negative earnings impact the overall attractiveness.

Positive Factors

Financial Stability

The company's balance sheet offers optionality even in tough conditions.

Market Potential

A federal re-scheduling in the U.S. should provide benefits including increased research, lower stigma, improve access to capital, and unlock the world's biggest addressable cannabis market.

Strategic Shift

ACB has turned over a proverbial new leaf following the reset in the cannabis industry, now with a focus on responsible growth.

Negative Factors

Industry Risks

There are lingering risks in the emerging cannabis industry including rampant illicit markets, limited insurance coverage, and unpredictable path to further de-regulation.

Operational Challenges

There are administration delays in settlement payments.

Aurora Cannabis Business Overview & Revenue Model

Company Description

Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

How the Company Makes Money

Aurora Cannabis primarily generates revenue through the sale of its cannabis products in both the medical and recreational markets. The company operates several production facilities, which allow it to cultivate and manufacture a wide array of cannabis products. Key revenue streams include direct sales to consumers through retail channels, wholesale distribution to other retailers, and export sales to international markets where cannabis is legal. Additionally, Aurora has formed significant partnerships and collaborations with other companies, enhancing its distribution capabilities and market reach. The company's revenue is also supported by ongoing investments in product development and innovation, which help maintain its competitive edge in the rapidly evolving cannabis industry.

Aurora Cannabis Financial Statement Overview

Summary

Aurora Cannabis shows modest revenue growth but struggles with profitability and cash flow. The balance sheet is stable with low leverage, yet the company faces challenges in generating positive returns on equity and cash flow.

Income Statement

Aurora Cannabis shows a modest revenue growth rate of 4.25% TTM, indicating some positive momentum. However, the company struggles with profitability, as evidenced by a negative EBIT margin and a very low net profit margin. The gross profit margin is relatively healthy at 54.65%, but the negative EBIT and net income highlight ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio is low at 0.18, suggesting manageable leverage levels. However, the return on equity is minimal at 0.28%, indicating inefficient use of equity capital. The equity ratio is not explicitly calculated, but the balance sheet shows a stable equity position relative to assets.

Cash Flow

Aurora Cannabis faces cash flow challenges, with negative free cash flow and a declining free cash flow growth rate. The operating cash flow to net income ratio is low, reflecting difficulties in converting earnings into cash. The negative free cash flow to net income ratio further underscores cash management issues.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	357.88M	343.29M	270.28M	233.29M	221.34M	245.25M
Gross Profit	140.64M	187.61M	131.46M	-64.36M	21.23M	-21.56M
EBITDA	24.75M	51.35M	-12.34M	-210.74M	-1.55B	-535.28M
Net Income	-20.14M	1.59M	-69.33M	-265.33M	-1.72B	-693.63M
Balance Sheet
Total Assets	837.84M	852.67M	838.67M	926.32M	1.08B	2.60B
Cash, Cash Equivalents and Short-Term Investments	186.03M	138.47M	117.47M	300.84M	439.14M	425.21M
Total Debt	101.63M	104.58M	104.79M	227.52M	269.49M	399.55M
Total Liabilities	249.16M	244.07M	236.80M	409.19M	422.00M	567.03M
Stockholders Equity	551.92M	567.17M	559.77M	486.08M	661.84M	2.04B
Cash Flow
Free Cash Flow	-999.00K	-2.85M	-85.46M	-127.95M	-142.48M	-263.66M
Operating Cash Flow	17.75M	16.00M	-68.51M	-115.82M	-110.27M	-210.58M
Investing Cash Flow	-20.18M	-14.33M	-5.49M	-27.29M	-36.17M	-26.91M
Financing Cash Flow	3.77M	-116.00K	-47.92M	-56.48M	147.78M	521.95M

Aurora Cannabis Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.69
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ACB, the sentiment is Neutral. The current price of 6.69 is below the 20-day moving average (MA) of 6.95, above the 50-day MA of 6.48, and above the 200-day MA of 6.61, indicating a neutral trend. The MACD of 0.18 indicates Positive momentum. The RSI at 47.99 is Neutral, neither overbought nor oversold. The STOCH value of 46.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:ACB.

Aurora Cannabis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACB	52 Neutral	$377.68M	105.83	-0.70%	―	28.42%	48.33%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
CGC	―	$500.01M	―	-98.42%	―	―	―
OGI	―	$214.03M	113.38	1.86%	―	―	―
CRON	―	$956.82M	52.63	1.73%	―	―	―
SNDL	61 Neutral	$635.78M	―	-8.30%	―	0.70%	15.62%
TLRY	50 Neutral	$1.38B	―	-88.27%	―	4.10%	-594.06%

Aurora Cannabis Corporate Events

Aurora Cannabis Announces 2025 AGM Results and Board Changes

Aurora Cannabis Inc. announced the results of its 2025 Annual General and Special Meeting, where shareholders voted on various resolutions, including the election of directors and the appointment of auditors. Theresa Firestone resigned from the Board of Directors, and Michael Singer was appointed as the new Lead Independent Director and Chair of the Human Resources and Compensation Committee. The meeting also saw the approval of amendments to the company’s RSU Plan, PSU Plan, and Share Option Plan, although the advisory vote on executive compensation did not pass.

The most recent analyst rating on (TSE:ACB) stock is a Buy with a C$9.00 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.

Aurora Cannabis Urges Shareholders to Vote Ahead of 2025 Meeting

Aurora Cannabis Inc. has reminded its shareholders to vote in advance of the proxy voting deadline for its 2025 Annual General and Special Meeting of Shareholders. The meeting is scheduled for August 8, 2025, and shareholders are encouraged to vote by August 6, 2025. The Board of Directors recommends voting for all director nominees and proposed resolutions. This announcement underscores the importance of shareholder participation in the company’s governance and could impact the company’s strategic direction and stakeholder interests.

The most recent analyst rating on (TSE:ACB) stock is a Buy with a C$9.00 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.

Aurora Cannabis Schedules Q1 2026 Financial Results Conference Call

Aurora Cannabis announced it will host a conference call on August 6, 2025, to discuss its financial results for the first quarter of 2026. The call will be led by CEO Miguel Martin and CFO Simona King, and it aims to provide insights into the company’s financial performance and strategic direction. This announcement is significant as it reflects Aurora’s ongoing commitment to transparency and engagement with investors, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$8.50 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.

Aurora Cannabis Achieves EU-GMP Certification for Distribution Centre

Aurora Cannabis Inc. has achieved its first-ever EU-GMP certification for its dedicated distribution centre in Brampton, Ontario, enhancing its international export capabilities. This certification, which aligns with European Union standards, allows Aurora to optimize its global supply chain and ensure consistent access to high-quality medical cannabis for patients worldwide, reinforcing its position as a leading exporter in the industry.

The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$8.50 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.

Aurora Cannabis Announces Shareholder Meeting Details

Aurora Cannabis Inc. has announced the availability of its management information circular for the upcoming annual general and special meeting of shareholders. The meeting, scheduled for August 8, 2025, will be held virtually, allowing shareholders worldwide to participate. Aurora’s board recommends voting in favor of all director nominees and meeting resolutions, emphasizing the importance of shareholder participation. This announcement underscores Aurora’s commitment to transparent governance and active shareholder engagement, potentially impacting its industry positioning and stakeholder relations.

The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$8.50 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.

Aurora Cannabis to Discuss Fiscal Year 2025 Results in Upcoming Investor Call

Aurora Cannabis announced it will host a conference call on June 18, 2025, to discuss its fourth quarter and fiscal year 2025 financial results. This announcement highlights the company’s commitment to transparency and engagement with investors, which could impact its market positioning and stakeholder relations positively.

The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$11.00 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.